# OnCo record irae-diabetes (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/irae-diabetes/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "irae-diabetes" ;
  schema:name "Immune-related type 1 diabetes and diabetic ketoacidosis from checkpoint inhibitors"@en ;
  schema:alternateName "checkpoint inhibitor diabetes"@en, "ICI-induced diabetes"@en, "ir-T1DM"@en, "CPI-DM"@en, "CIADM"@en, "immunotherapy diabetes"@en, "checkpoint inhibitor DKA"@en ;
  schema:description "Rarely, immunotherapy destroys the cells that make insulin. Blood sugar can rise within days and become dangerous (diabetic ketoacidosis). Thirst, passing a lot of urine, being sick or feeling drowsy need urgent help. It is treated with insulin, which is almost always lifelong, and not with steroids."@en ;
  schema:url <https://onco.cc/protocols/irae-diabetes/> ;
  schema:dateModified "2026-11-11"^^xsd:date ;
  onco:tag "protocol", "irae", "endocrine", "acute-oncology" ;
  onco:related <https://onco.cc/protocols/irae-thyroid/>, <https://onco.cc/protocols/irae-hypophysitis-adrenal/>, <https://onco.cc/protocols/checkpoint-inhibitor-baseline-and-monitoring/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/avelumab/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/tremelimumab/> ;
  onco:institutions <https://onco.cc/institutions/sitc/>, <https://onco.cc/institutions/asco/>, <https://onco.cc/institutions/esmo/> ;
  onco:terms <https://onco.cc/terms/immune-endocrinopathy/>, <https://onco.cc/terms/irae/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-asco-irae-guideline-jco-2021/> .